Trials / Completed
CompletedNCT05703841
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess what drug does to body when healthy Chinese participants receive single oral dose of JNJ-77242113.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77242113 | JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet. |
Timeline
- Start date
- 2023-02-14
- Primary completion
- 2023-04-07
- Completion
- 2023-04-12
- First posted
- 2023-01-30
- Last updated
- 2023-06-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05703841. Inclusion in this directory is not an endorsement.